Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
12.26
-0.34 (-2.70%)
At close: Jul 11, 2025, 4:00 PM
12.17
-0.09 (-0.73%)
After-hours: Jul 11, 2025, 4:04 PM EDT
Aardvark Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Aardvark Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $33, which forecasts a 169.17% increase in the stock price over the next year. The lowest target is $20 and the highest is $50.
Price Target: $33 (+169.17%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aardvark Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +226.26% | Jun 30, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $21 → $20 | Buy | Maintains | $21 → $20 | +63.13% | May 15, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $21 | Buy | Reiterates | $21 | +71.29% | Apr 1, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $50 | Buy | Reiterates | $50 | +307.83% | Apr 1, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $22 → $26 | Strong Buy | Maintains | $22 → $26 | +112.07% | Mar 27, 2025 |
Financial Forecast
Revenue This Year
n/a
from 20.49M
Revenue Next Year
n/a
EPS This Year
-2.99
from -5.15
EPS Next Year
-2.55
from -2.99
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | 3.2M | 42.0M |
| Avg | n/a | 1.0M | 20.5M |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | 4,017.6% |
| Avg | - | - | 1,909.0% |
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.61 | -2.37 | -1.68 |
| Avg | -2.99 | -2.55 | -2.89 |
| Low | -3.30 | -2.83 | -3.92 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.